COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN VERSUS RIVAROXABAN FOR NON-VALVULAR ATRIAL FIBRILLATION USING REAL-WORLD EVIDENCE IN MEDICARE BENEFICIARIES

被引：0
|
作者：
Peng, S. [1 ]
Deger, K. [1 ]
Ustyugova, A., V [2 ]
Gandhi, P. [3 ]
Qiao, N. [1 ]
Wang, C. [3 ]
Kansal, A. [1 ]
机构：
[1] Evidera, Bethesda, MD USA
[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[3] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV61
引用
收藏
页码：A269 / A270
页数：2
相关论文
共 50 条
  • [31] Effectiveness and Safety of Dabigatran and Warfarin in Real-World US Patients With Non-Valvular Atrial Fibrillation: A Retrospective Cohort Study
    Lauffenburger, Julie C.
    Farley, Joel F.
    Gehi, Anil K.
    Rhoney, Denise H.
    Brookhart, M. Alan
    Fang, Gang
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2015, 4 (04):
  • [32] Comparative Effectiveness of Dabigatran versus Warfarin in Patients With Non-Valvular Atrial Fibrillation
    Alonso, Alvaro
    Chen, Lin Y.
    MacLehose, Richard F.
    Lutsey, Pamela L.
    CIRCULATION, 2013, 128 (22)
  • [33] EFFECTIVENESS AND SAFETY OF APIXABAN, DABIGATRAN, AND RIVAROXABAN COMPARED TO WARFARIN AMONG NON-VALVULAR ATRIAL FIBRILLATION PATIENTS IN THE US MEDICARE POPULATION
    Amin, Alpesh
    Keshishian, Allison
    Trocio, Jeffrey
    Le, Hannah
    Dina, Oluwaseyi
    Zhang, Qisu
    Baser, Onur
    Vo, Lien
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 316 - 316
  • [34] Cost-effectiveness analysis of anticoagulation options for non-valvular atrial fibrillation in Iran
    Rezaei, Satar
    Bavandpour, Maryam
    Mobinizadeh, Mohammadreza
    Daroudi, Rajabali
    BMC RESEARCH NOTES, 2024, 17 (01)
  • [35] COST-EFFECTIVENESS OF APIXABAN VERSUS WARFARIN IN CHINESE PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Chan, E.
    Li, X.
    Lau, C.
    Anand, S.
    VALUE IN HEALTH, 2016, 19 (07) : A866 - A867
  • [36] Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation
    Miguel, Luis Silva
    Ferreira, Jorge
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2016, 35 (03) : 141 - 148
  • [37] COST EFFECTIVENESS OF ORAL ANTICOAGULATION THERAPY FOR NON-VALVULAR ATRIAL FIBRILLATION PATIENTS: WARFARIN VERSUS THE NEW ORAL ANTICOAGULANTS RIVAROXABAN, DABIGATRAN AND APIXABAN
    Ortiz-Cartagena, Ismael
    Gotay, Antonio Orraca
    Acevedo, Jose
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 490 - 490
  • [38] Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: A real-world experience
    Akhtar, Tauseef
    Fratti, Juan Del Cid
    Mattumpuram, Jishanth
    Fugar, Setri
    Uprety, Alok
    Nwaichi, Chineme
    Torres, Andrea
    Mann, Hashim
    Golzar, Yasmeen
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 320 : 78 - 82
  • [39] ESTIMATION OF THE COST-EFFECTIVENESS OF APIXABAN IN NON-VALVULAR ATRIAL FIBRILLATION IN ARGENTINA
    Giorgi, M. A.
    Caroli, C.
    Micone, P.
    Giglio, N. D.
    Aiello, E. C.
    Donato, B. M. K.
    Mould, J. F.
    Radero, G.
    Casas, M.
    VALUE IN HEALTH, 2013, 16 (07) : A666 - A666
  • [40] Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice
    Li, Xiaoyan
    Deitelzweig, Steve
    Keshishian, Allison
    Hamilton, Melissa
    Horblyuk, Ruslan
    Gupta, Kiran
    Luo, Xuemei
    Mardekian, Jack
    Friend, Keith
    Nadkarni, Anagha
    Pan, Xianying
    Lip, Gregory Y. H.
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (06) : 1072 - 1082
12345